We conducted an prospective nonrandomized interventional study to compare the efficacy of a newer therapeutic agent Centchroman with established therapeutic agents Danazol and Evening Primrose Oil ( EPO ) in the treatment of mastalgia and fibroadenoma. Total 117 patients have been participated in the study (mastalgia–68, fibroadenoma–54 and 5 patients have both). In mastalgia group 28 ，18 and 22 patients were treated with Centchroman, Danazol and EPO respectively. In fibroadenoma group 17 ，18 and 19 patients received Centchroman, Danazol and EPO respectively. Centchroman was found to be the most effective drug with the post intervention pain scores <2 in 71% patients (50% with Danazole , 0% with EPO). In fibroadenoma group complete response rate was highest in Centchroman arm (29%)  in comparison to Danazol (17 %) and EPO (0%) respectively. Side effects are maximum with Danazole and Centchroman is the cheapest.